ANEB Anebulo Pharmaceuticals, Inc.

Fundamentals / CIK 0001815974 / USD

Anebulo Pharmaceuticals, Inc. reported $9.42M in total assets and a net loss of $7.98M through June 30, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ANEB in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

5 fiscal years (2021 to 2025), reported in USD.

$0$0$0-$28.29MFY 2021 Net Income: -$30.25M2021FY 2022 Net Income: -$6.83M2022FY 2023 Net Income: -$11.73M2023FY 2024 Net Income: -$8.20M2024FY 2025 Net Income: -$8.48M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Jun 30 Jun 30 Jun 30 Jun 30 Jun 30
Research & Development $4.30M $3.55M $5.60M $2.96M $2.27M
Total Operating Expenses $9.22M $8.31M $11.78M $6.83M $3.61M
Operating Income -$9.22M -$8.31M -$11.78M -$6.83M -$3.61M
Interest Income $258K $249K $92K $7.3K $1.0K
Interest Expense $400K $200K -- -- $12K
Income Before Tax -- -- -- -- -$3.61M
Net Income -$8.48M -$8.20M -$11.73M -$6.83M -$30.25M
Basic EPS -$0.25 -$0.32 -$0.47 $0.29 -$2.83
Diluted EPS -$0.25 -$0.32 -$0.47 $0.29 -$2.83
Basic Shares Outstanding 33.8M 25.8M 25.1M 23.3M 13.6M
Diluted Shares Outstanding 33.8M 25.8M 25.1M 23.3M 13.6M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Research & Development $1.16M $810K $1.13M $638K $1.22M $1.31M $468K $748K
Total Operating Expenses $2.62M $2.26M $2.33M $1.89M $2.59M $2.41M $1.34M $1.66M
Operating Income -$2.62M -$2.26M -$2.33M -$1.89M -$2.59M -$2.41M -$1.34M -$1.66M
Interest Income $85K $110K $123K $102K $7.1K $26K $50K $68K
Interest Expense $17K $17K $300K $100K $100K $100K -- $60K
Net Income -$2.00M -$2.16M -$2.14M -$1.68M -$2.46M -$2.20M -$1.35M -$1.65M
Basic EPS -$0.05 -$0.05 -- -$0.04 -$0.09 -$0.08 -- -$0.06
Diluted EPS -$0.05 -$0.05 -- -$0.04 -$0.09 -$0.08 -- -$0.06
Basic Shares Outstanding 41.1M 41.1M -- 41.1M 27.4M 25.9M -- 25.9M
Diluted Shares Outstanding 41.1M 41.1M -- 41.1M 27.4M 25.9M -- 25.9M

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Jun 30 Jun 30 Jun 30 Jun 30 Jun 30 Jun 30
Cash & Cash Equivalents $11.63M $3.09M $11.25M $14.55M $19.99M $3.02M
Cash & Short-Term Investments $11.63M $3.09M $11.25M $14.55M $19.99M $3.02M
Total Current Assets $11.96M $3.51M $11.67M -- -- $3.03M
Other Non-Current Assets $183K $565K -- -- -- --
Total Non-Current Assets $183K $565K $0 -- -- $0
Total Assets $12.15M $4.07M $11.67M $15.58M $21.65M $3.03M
Accounts Payable $224K $156K $535K $381K $110K --
Total Current Liabilities -- -- -- -- -- $224K
Total Non-Current Liabilities -- -- -- -- -- $0
Total Liabilities $488K $261K $1.07M $513K $242K $224K
Common Stock $41K $26K $26K $23K $23K $12K
Retained Earnings -$73.89M -$65.40M -$57.20M -$45.47M -$38.64M -$183K
Total Stockholders' Equity $11.66M $3.81M $10.60M $15.07M $21.41M -$171K
Total Equity $11.66M $3.81M $10.60M $15.07M $21.41M -$171K

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Cash & Cash Equivalents $9.04M $10.35M $11.63M $13.28M $15.00M $1.40M $3.09M $5.15M
Cash & Short-Term Investments $9.04M $10.35M $11.63M $13.28M $15.00M $1.40M $3.09M $5.15M
Total Current Assets $9.27M $10.54M $11.96M $13.81M $15.40M $1.96M $3.51M $5.37M
Other Non-Current Assets $148K $166K $183K $201K $446K $505K $565K $625K
Total Non-Current Assets $148K $166K $183K $201K $446K $505K $565K $625K
Total Assets $9.42M $10.70M $12.15M $14.01M $15.84M $2.47M $4.07M $6.00M
Accounts Payable $555K $608K $224K $428K $320K $252K $156K $385K
Total Liabilities $1.49M $964K $488K $546K $879K $569K $261K $1.01M
Common Stock $41K $41K $41K $41K $41K $26K $26K $26K
Retained Earnings -$78.05M -$76.05M -$73.89M -$71.74M -$70.07M -$67.60M -$65.40M -$64.05M
Total Stockholders' Equity $7.94M $9.74M $11.66M $13.46M $14.96M $1.90M $3.81M $4.99M
Total Equity $7.94M $9.74M $11.66M $13.46M $14.96M $1.90M $3.81M $4.99M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Jun 30 Jun 30 Jun 30 Jun 30 Jun 30
Net Income -$8.48M -$8.20M -$11.73M -$6.83M -$30.25M
Stock-Based Compensation $1.45M $759K $885K $481K $200K
Change in Payables $68K -$378K $154K $271K $110K
Operating Cash Flow -$6.35M -$8.09M -$9.68M -$5.44M -$4.87M
Common Stock Issued $15.00M -- $6.65M -- $20.60M
Financing Cash Flow $14.88M -$62K $6.38M -- $21.83M
Net Change in Cash $8.53M -$8.15M -$3.30M -$5.44M $16.96M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Net Income -$2.00M -$2.16M -$2.14M -$1.68M -$2.46M -$2.20M -$1.35M -$1.65M
Stock-Based Compensation $199K $238K $340K $300K $564K $287K $177K $200K
Change in Payables -$53K $383K -$203K $146K $30K $96K -$228K $66K
Operating Cash Flow -$1.31M -$1.27M -$1.65M -$1.60M -$1.41M -$1.69M -$2.05M -$1.50M
Net Change in Cash -$1.31M -$1.27M -$1.65M -$1.72M $13.59M -$1.69M -$2.05M -$1.50M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Jun 30 Jun 30 Jun 30 Jun 30 Jun 30
Return on Equity (ROE) -72.8% -215.1% -110.7% -45.3% -141.3%
Return on Assets (ROA) -69.9% -201.4% -100.5% -43.8% -139.7%
EPS Growth (YoY) -- -- -262.1% -- --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Return on Equity (ROE) -100.5% -86.7% -72.8% -57.1% -51.2% -417.2% -215.1% -187.5%
Return on Assets (ROA) -84.7% -78.9% -69.9% -54.9% -48.4% -321.0% -201.4% -155.9%
Source: SEC EDGAR CompanyFacts (CIK 0001815974) · from June 30, 2020 Data through December 31, 2025 · synced Nov 21, 2026, 05:06 UTC · Open in terminal